Top

Published in:

Open Access 01-04-2019 | Original Article

Genetic counselling of young women with breast cancer for Li–Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals

Authors: J. J. Bakhuizen, M. E. Velthuizen, S. Stehouwer, E. M. Bleiker, M. G. Ausems

Published in: Familial Cancer | Issue 2/2019

Abstract

Germline TP53 mutations are associated with an increased risk of early-onset breast cancer. Traditionally, it was not standard practice to offer TP53 genetic testing due to the low mutation detection rate and limited options regarding preventive screening. Recent guidelines recommend that all women diagnosed with breast cancer before the age of 31, irrespective of family history, should be offered TP53 genetic testing. This study aims to gain more knowledge on the attitudes and experiences among genetics professionals regarding the timing and content of genetic counselling of young breast cancer patients for Li–Fraumeni syndrome (LFS). We conducted a nationwide online survey among genetics professionals who provide cancer genetic counselling in the Netherlands. Fifty-seven professionals completed the questionnaire (response rate overall 54%, clinical geneticists 70%). Most respondents reported that they discuss the option of TP53 genetic testing—simultaneously with BRCA 1/2—during the initial counselling visit, especially in case of referral for treatment-focused genetic counselling. There was a general consensus about ten information items that should be discussed during counselling. Sixty-one percent of genetics professionals did not encounter difficulties in providing genetic counselling for LFS, but a substantial minority (29%) did. This study offers valuable insight, which will be useful for clinical practice. Studies which address young breast cancer patients’ attitudes and preferences regarding the timing and content of counselling are warranted to further determine the most appropriate genetic counselling strategy for these women.

Available only for authorised users

NABON (2017) Breast cancer, Dutch guideline. http://www.oncoline.nl/borstkanker. Accessed 25 May 2018

Netherlands Comprehensive Cancer Organisation (IKNL) (2017) Dutch cancer Figs. 2017. http://www.cijfersoverkanker.nl/. Accessed 21 May 2018

Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345. https://doi.org/10.1146/annurev.genom.9.081307.164339 CrossRefPubMed

Tung N, Lin NU, Kidd J et al (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34(13):1460–1468. https://doi.org/10.1146/annurev.genom.9.081307.164339 CrossRefPubMedPubMedCentral

Claus EB, Risch NJ, Thompson D (1990) Age at onset as an indicator of familial risk of breast-cancer. Am J Epidemiol 131(6):961–972. https://doi.org/10.1093/oxfordjournals.aje.a115616 CrossRefPubMed

Adank MA, Hes FJ, van Zelst-Stams WAG et al (2015) CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer. Ned Tijdschr Geneeskd 159:A8910PubMed

National Comprehensive Cancer Network (2018) NCCN Clinical Practice Guidelines in Oncology: genetic/familial high risk assessment: breast and ovarian (Version I.2018). https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (registration required). Accessed 21 May 2018

Schneider K, Zelley K, Nichols KE et al (1999) Li–Fraumeni syndrome. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews. University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1311/. Accessed 11 Apr 2013

Bouaoun L, Sonkin D, Ardin M et al (2016) TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat 37(9):865–876. https://doi.org/10.1002/humu.23035 CrossRefPubMed

10.

Tinat J, Bougeard G, Baert-Desurmont S et al (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27(26):e108–e109. https://doi.org/10.1200/JCO.2009.22.7967 CrossRefPubMed

11.

Lalloo F, Varley J, Moran A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42(8):1143–1150. https://doi.org/10.1016/j.ejca.2005.11.032 CrossRefPubMed

12.

Gonzalez KD, Noltner KA, Buzin CH et al (2009) Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256. https://doi.org/10.1200/JCO.2008.16.6959 CrossRefPubMed

13.

Ginsburg OM, Akbari MR, Aziz Z et al (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8(4):563–567. https://doi.org/10.1007/s10689-009-9287-z CrossRefPubMed

14.

Mouchawar J, Korch C, Byers T et al (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70(12):4795–4800. https://doi.org/10.1158/0008-5472.CAN-09-0851 CrossRefPubMedPubMedCentral

15.

McCuaig JM, Armel SR, Novokmet A et al (2012) Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 11(4):607–613. https://doi.org/10.1007/s10689-012-9557-z CrossRefPubMed

16.

Bougeard G, Renaux-Petel M, Flaman JM et al (2015) Revisiting Li–Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33(21):2345–2352. https://doi.org/10.1200/JCO.2014.59.5728 CrossRefPubMed

17.

Netherlands Foundation for the Detection of Hereditary Tumours (STOET) and the Dutch Society of Clinical Genetics (VKGN) (2005) Erfelijke tumoren: richtlijnen voor diagnostiek en preventie. Edition 2005

18.

Netherlands Foundation for the Detection of Hereditary Tumours (STOET) and the Dutch Society of Clinical Genetics (VKGN) (2010) Erfelijke tumoren: richtlijnen voor diagnostiek en preventie. Edition 2010

19.

Netherlands Foundation for the Detection of Hereditary Tumours (STOET) and the Dutch Society of Clinical Genetics (VKGN) (2017) Erfelijke tumoren: richtlijnen voor diagnostiek en preventie. Edition 2017

20.

Bakhuizen JJ, Hogervorst FB, Velthuizen ME (2018) Early-onset sporadic breast cancer: an indication for routine TP53 germline mutation testing? (manuscript in submission)

21.

UMC Utrecht Julius Centrum (2017) Research online. http://www.researchonline.info. Accessed 7 May 2017

22.

Stichting Diagnose Kanker (SDK), European Li–Fraumeni Families Foundation (ELFF) (2014) Zorgstandaard Li–Fraumeni Syndroom. Edition 2014. http://www.zorginzicht.nl/bibliotheek/ll-fraumeni-syndroom/KwaliteitsstandaardenDocumenten/Zorgstandaard-li-fraumeni.pdf. Accessed 10 May 2017

23.

McBride KA, Ballinger ML, Killick E et al (2014) Li–Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 11(5):260–271. https://doi.org/10.1038/nrclinonc.2014.41 CrossRefPubMed

24.

Villani A, Tabori U, Schiffman J et al (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li–Fraumeni syndrome: a prospective observational study. Lancet Oncol 12(6):559–567. https://doi.org/10.1016/S1470-2045(11)70119-X CrossRefPubMed

25.

Villani A, Shore A, Wasserman JD et al (2016) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li–Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17(9):1295–1305. https://doi.org/10.1016/S1470-2045(16)30249-2 CrossRefPubMed

26.

Kratz CP, Achatz MI, Brugieres L et al (2017) Cancer screening recommendations for individuals with Li–Fraumeni syndrome. Clin Cancer Res 23(11):e38–e45. https://doi.org/10.1158/1078-0432.CCR-17-0408 CrossRefPubMed

27.

Ruijs MWG, Loo CE, van Buchem CAJM, et al (2017) Surveillance of Dutch patients with Li–Fraumeni syndrome: the LiFe-Guard Study. JAMA Oncol 3(12):1733–1734. https://doi.org/10.1001/jamaoncol.2017.1346 CrossRefPubMedPubMedCentral

28.

Peterson SK, Pentz RD, Marani SK et al (2008) Psychological functioning in persons considering genetic counseling and testing for Li–Fraumeni syndrome. Psychooncology 17(8):783–789. https://doi.org/10.1002/pon.1352 CrossRefPubMed

29.

Lammens CR, Aaronson NK, Wagner A et al (2010) Genetic testing in Li–Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 28(18):3008–3014. https://doi.org/10.1200/JCO.2009.27.2112 CrossRefPubMed

30.

Lammens CR, Bleiker EM, Verhoef S et al (2011) Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes. Psychooncology 20(6):631–638. https://doi.org/10.1002/pon.1951 CrossRefPubMed

31.

Cook JV, Dickinson HO, Eccles MP (2009) Response rates in postal surveys of healthcare professionals between 1996 and 2005: an observational study. BMC Health Serv Res 9:160. https://doi.org/10.1186/1472-6963-9-160 CrossRefPubMedPubMedCentral

Title: Genetic counselling of young women with breast cancer for Li–Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals
Authors: J. J. Bakhuizen
M. E. Velthuizen
S. Stehouwer
E. M. Bleiker
M. G. Ausems
Publication date: 01-04-2019
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 2/2019
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-018-0103-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature

Interest in, willingness-to-pay for and willingness-to-recommend genetic testing for prostate cancer among affected men after radical prostatectomy

Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes

Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013–2018)

Development and pilot testing of a leaflet informing women with breast cancer about genomic testing for polygenic risk

Massive juvenile polyposis of the stomach in a family with SMAD4 gene mutation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer